Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hOMSC200 for Chronic Diabetic Foot Ulcers
NCT06003530Phase 1Active, not recruiting
- Sponsor
- Cytora
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hOMSC200 in diabetic foot ulcer (DFU) (3 arms), sponsored by Cytora. Primary endpoint: Treatment related adverse events at 6 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
hOMSC200
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06003530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003530.